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Prostate Cancer (PCa) is progressively more common diagnosis in Western societies and in those 
following Western lifestyles and diets. Despite progresses in prevention and early detection, 
refinements in surgical technique and improvements in adjuvant radio-therapy and chemotherapy, the 
aptitude to cure many patients with prostate cancer remains elusive. Various efforts have been made to 
assess the effects of cytokine gene polymorphisms on the risk of prostate cancer among different 
population. Interleukin-6 (IL-6) has an important role during prostate cancer progression and there has 
been reports that the IL-6 levels in the serum of patients with hormone refractory and metastatic 
prostate cancer are significantly increased compared with those in patients with hormone sensitive and 
localized prostate cancer.  However, the result regarding its risk is yet to be comprehensive. The aim of 
the present study was to evaluate IL-6 – 174 G>C polymorphism and risk of PCa among 150 prostate 
cancer patients and equal number of age matched control groups. For this case control study 150 
prostate cancer patients, 150 BPH (benign hyperplasia) and 150 health controls were recruited. DNA 
was isolated by Phenol, chloroform method and the PCR-RFLP (Polymerase chain reaction- Restriction 
Fragment length Polymorphism) was employed to amplify and create a restriction site on the gene of 
interest. There was statistically increased risk of PCa among cases (OR= 1.77, 95%CI, 0.65-4.91, p<0.05   
) who contained the CC genotype when compared with health controls. Moreover, the same genotype 
has elevated the relative risk (OR, 1.63, 95% CI, 1.01-2.62, p<0.05) when smoking has been take into 
account. 
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INTERODUCTION  
 
Among men, prostate cancer has a high prevalence, with 
relatively lower cancer-specific mortality risk compared to 
lung and colon cancer. Prostate-specific antigen (PSA) 
screening has increased prostate cancer awareness 
since its implementation as a screening tool almost 25 
years ago, but, due to the largely indolent course of this 
disease and the unspecific nature of the PSA test, 
increased incidence has largely been  observed  
(Barqawi et al., 2012). Accounting for 29% of all cancers 
in men, prostate cancer is the most common cancer 
among men behind nonmelanoma skin cancer and is the 
second highest cause of cancer death among men of all 
races (Jemal et al., 2010, Siegel et al., 2011). Interleukin-
6 (IL-6) is an immunoregulatory pleiotropic cytokine that 
activates a cell-surface signaling assembly composed of 
IL6, IL6RA, and the shared signaling receptor gp130 
(Boulanger et al., 2003). The cytokine is involved in 
different physiological and pathophysiological processes,  
  
 
 
 
 
such as inflammation, bone metabolism, synthesis of 
CRP (C-reactive protein), and carcinogenesis (Diehl and 
Rincón, 2002). The gene encoding IL-6 is localized at 
chromosome 7p21–14.1 (Akira, 1993). It is a glycoprotein 
consisting of 212 amino acids. The expression of IL-6 
and its receptor has been consistently demonstrated, not 
only in human prostate cancer cell lines, but more 
importantly in human prostate carcinoma and benign 
prostate hyperplasia, while tissue specimens from 
patients with organ confined prostate cancer have higher 
IL-6 and IL-6 receptor levels (Hobisch et al., 2000; Giri et 
al., 2001) Multiple studies have demonstrated that IL-6 is 
increased in the serum of patients with metastatic 
prostate cancer and IL-6 levels correlate with tumor 
burden as well as with serum prostate specific antigen 
(PSA) or clinical evident metastases (Alder et al., 1999; 
Drachenberg et al.,1999). A common G>C polymorphism 
at position -174 of the interleukin-6 (IL-6) gene promoter 
is thought to affect the expression level of this gene, thus 
predisposing to a variety of diseases, including 
tumorigenesis (Litovkin et al., 20007).   Interleukin-6 (IL-
6) is a proinflammatory cytokine produced by a number of 
cell types including cancer cells (Conze et al., 2001). 
Elevated levels of circulating interleukin-6 have been 
seen in many clinical situations characterized by tissue 
injury, such as trauma (including major surgery), burns, 
malignant conditions, exposure to toxins and aseptic 
irritants, immune hypersensitivity reactions, inflammatory, 
infectious and autoimmune diseases (Papanicolaou et 
al., 1998). As a growth factor IL-6 plays a significant role 
in cell differentiation and is believed to be involved in 
tumor progression (Hirano, 1998). High IL-6 levels have 
been shown to correlate with poor prognosis and high 
mortality in prostate and colorectal cancer patients 
(Nakashima et al., 2000; Chung et al., 2003). Cytokine 
polymorphisms, possibly associated with differential 
cytokine production, are risk factors for recurrent prostate 
cancer. The 174 IL-6 G>C genotype appears to be 
biologically and clinically important. There is increasing 
evidence that IL-6 gene polymorphism is associated with 
altered levels of IL-6 expression (Tan et al., 2005). 
Therefore, the present study aimed to assess the effect 
of this gene polymorphism towards risk of prostate 
cancer in north Indian population.  
 
 
MATERIALS AND METHODS  
 
Blood samples from 150 north Indian males with prostate 
cancer were collected in sterile EDTA-K2 coated non-
vacationous tubes (Becton–Dickinson, San Jose, CA, 
USA). The samples were collected at the Departments of 
Urology of the Postgraduate Institute of Medical 
Education and Research (PGIMER), Chandigarh, India, 
the All India Institute of Medical Sciences (AIIMS), New 
Delhi   and  Government  Medical  College  and  Hospital,  
 
 
 
 
Patiala, Punjab in north India. All patients were 
histologicaly diagnosed carcinoma of the prostate 
confirmed with biopsy studies as well as prostate specific 
antigens (PSA) test. There were 300 age matched control 
samples, of which 150 were free from any symptom of 
disease, whereas the rest 150 were diagnosed with 
benign prostate hyperplasia (BPH). All the samples were 
not originated from the same hospital; however, all of the 
individuals recruited for this study were in the same 
geographical area. None of the patients were given either 
chemo or radiotherapy before providing the sample. The 
samples were collected by the clinical staff of the 
hospitals concerned. A detailed questionnaire designed 
by the Indian Council of Medical Research (ICMR) 
encompassing details of the disease diagnosis, family 
history, age, smoking and drinking status was completed 
at the time of collection of the samples. Besides, the 
pathological grading and staging of the cancer was 
confirmed from the hospital record. Blood samples were 
stored at -800C till extraction of DNA. Written informed 
consent was obtained from all cases and controls. The 
study was carried out after obtaining approval from the 
Ethics Committee of the PGIMER, Chandigarh, India. 
 
 
Genotyping of IL-6- 174 G>C  
 
Genomic DNA was extracted from peripheral blood 
lymphocytes by standardized protienase K digestion and 
phenol– chloroform extraction. A PCR- RFLP technique 
was utilized to amplify IL- 6 - 174 G>C polymorphism 
according to the protocol given by Sery et al. (2003). The 
primer sequences used to amplify 204 bp PCR products 
were, forward 5’-ACTTTTCCCCCTAGTTGTTTCTTTC-3’ 
and reverse 5’-AGACATGAGCCTCAGACATCTCAGT-3’. 
The PCR reaction was performed in a total volume of  
50µl containing  200ng of genomic DNA, 200µM of each 
dNTP, 50mM KCl, 1mM each of the primers and 1.5 U of 
Taq polymerase. (Sigma Alderich, USA). The PCR 
conditions utilized to amplify the gene were an initial 
denaturation step of 5min at 95°C coupled to 35cycles of 
45s at 95°C, 30s at 55°C and 45s at 74 °C, followed by 
74 °C for 6 min that amplified 204 bp PCR products (Fig. 
1). RFLP of IL 6 was performed in a total reaction volume 
of 10µl, where 2µl of 204 bp PCR product, 1.8µl of buffer, 
8 U of TaqI restriction enzyme and 5.2µl of distilled water 
were mixed together and incubated for 5 hours at 65oC.  
The digested product was analyzed by 2.5% agarose gel 
electrophoresis containing ethidium bromide. The 204 bp 
product was cleaved in two fragments of 180 and 24 bp 
by Taq I enzyme. The uncut product of 204 bp identified 
CC and the cut fragment identified GG genotype.  The 
heterozygous GC genotype was identified by the 
presence of both 204 and 180 bp products (Fig. 2). 
 
 
  
 
 
 
 
 
Fig 1 204 bp PCR amplification product of IL-6-174 G>C gene  
Lanes 1-7, 204 bp PCR product 
Lane 8 100 bp DNA marker  
 
 
 
Fig 2 representative agarose gel electrophoresis of IL-6 gene after digestion with Taq I enzyme  
Lane 10 100 bp DNA ladder  
Lanes 1,3,5,6, and 9 heterozygous GC 204,180 bp  
Lanes 2 and 8 homozygous CC 204 bp  
Lanes 4 and 7 Homozygous GG 180 bp  
 
 
Table 1 IL-6 174 G-C genotype frequency, OR and 95% CI for prostate cancer among cases and controls.  
 
Genotype  Cases Controls OR (95% CI) 
GG 82 (54.7%) 84 (56.0%) 1.0 Ref. 
GC 54 (36%) 58 (38.7%) 0.94 (0.57-1.57) 
CC 14 (9.3%) 8 (5.3%) 1.77 (0.65-4.91) 
Allelic frequency  
218 
 
226 
 
1.0 Ref. G 
C 82 74 1.14 (0.78-1.67) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (centre for disease control and prevention ). 
 
Statistical Analysis 
 
Relevant data of cases, BPH and health controls such as 
age, inhabitancy, occupation, smoking, stage of the 
disease and drinking habits were tabulated. The effect 
risk of PCa was analyzed by computing odds ratio (OR) 
and 95 % confidence interval (CI). The statistical analysis 
was performed using Epi-Info software (Epi-Info, version 
3.5.1. Center for Disease Control and Prevention, 
Atlanta, GA, USA, August 13, 2008) and software SPSS 
version 11.5 (SPSS, Chicago, IL). Chi square test was 
utilized to check for the Hardy–Weinberg’s equilibrium. 
Significance was set at p<0.05. 
 
 
RESULTS  
 
 
Study Population  
 
The Demographic characteristics of study subjects were 
reported elsewhere. There were no significance 
difference in the age of cases, BPH and health controls.  
and association of the I  polymorphism on 
  
 
 
 
 
Table 2 IL-6 -174 G-C   genotype frequencies and OR and 95% CI for prostate cancer among cases and BPH. 
 
Genotype  Cases BPH OR (95% CI) 
GG 82 (54.7%) 80 (53.3%) 1.0 Ref.  
GC 54 (36%) 60 (40%) 0.80 (0.53-1.46) 
CC 14 (9.3%) 10 (6.7%) 1.37 (0.80-1.67) 
Allelic frequency  
218 
 
220 
 
1.0 Ref. G 
C 82 80 1.03 (0.71-1.51) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (center for disease control and prevention). 
 
Table 3 Risk of prostate cancer in smokers due to IL-6-174 G-C polymorphisms among cases and controls. 
 
 
Genotype  
       Smokers   
OR (95% CI) 
       Non smokers    
 OR (95% CI) cases Controls   cases Controls  
GG 26 (17.3%) 24 (16%) 1.16 (0.57-
2.38) 
56 (ref.)  
(37.3%)  
60 (ref.)   
(40%)  
1.0 
GC 18 (12%) 15 (10%) 1.29 (0.55-
3.00) 
36 (24%) 43 (28.7%) 0.97(0.44-2.10) 
CC 4 (2.7%) 1 (0.7%) 1.66 (1.03-
2.67) 
10 (6.7%) 7 (4.7%) 1.20 (0.52-2.80) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (center for disease control and prevention ). 
 
Table 4 Risk of prostate cancer in smokers due to IL-6-174 G-C polymorphisms among cases and BPH. 
 
 
Genotype  
       Smokers   
OR (95% CI) 
       Non smokers    
 OR (95% CI) cases BPH cases BPH 
GG 26 (17.3%) 22 (14.7%) 1.22 (0.59-
2.54) 
56 (ref.) 
(37.3%) 
58 (ref.) 
(38.7%) 
1.0 
GC 18 (12%) 13 (8.7%) 1.43 (0.60-
3.45) 
36 (24%) 47 (31.3%) 0.58 (0.39-1.85) 
CC 4 (2.7%) 1 (0.7%) 1.63 (1.01-
2.62) 
10 (6.7%) 9 (6.0%) 0.97 (0.40-2.33) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (center for disease control and prevention ). 
 
The study comprised both rural and urban as described 
previously (Berhane et al., 2012). In this case control 
study sedentary, manual and industrial workers were 
involved.  The genotype frequency of IL-6 G>C 
polymorphism in cases and controls is describe in Table 
1. The percentage of GG genotype in cases was 54.7 
unlike 56 percent in controls. The percentage of the 
heterozygous GC genotype in cases was 36 and it was 
38 in controls. The percentage of the homozygous variant 
CC genotype in cases was 9.3% unlike 5.3 % in controls. 
The G allele frequency was 0.73 in cases and it was 0.75 
in controls. On the other hand the C allele frequency was 
0.27 in cases and it was 0.25 in controls. Statistically 
significant 1.77 folds of increased risk of prostate cancer 
was observed in cases due to the CC genotype of IL- 6 
(OR=1.77, 95% CI=0.65-4.91, p<0.05). 
The frequency of the three genotypes of IL-6 among 
cases and BPH study subjects is given in Table 2. The 
percentages of GG, GC and CC genotypes in BPH study 
subjects were 53.3, 40 and 6.7, respectively. There was 
no statistically significance association towards risk of 
prostate cancer among cases when it is computed with 
BPH study subjects.  
The relative risk of prostate cancer due to smoking and 
IL-6 gene polymorphism among cases and controls is 
given in Table 3. The percentages of the three genotypes 
among smoker cases were 17.3, 12 and 2.7 for GG, GC 
and CC, respectively. OR and 95% CI of smoker cases 
was computed with healthy non smoker controls. 1.66 
folds of statistically significant increased risk of prostate 
cancer was association due to smoking for CC genotype 
carriers (OR=1.66, 95% CI=1.03-2.67, p<0.05). 
The relative risk of prostate cancer due to smoking and 
IL-6 174 G-C gene polymorphism among cases and BPH 
study subjects is given in Table 4. The genotype 
frequency of smokers in BPH subjects was 14.7 GG, 8.7 
GC and 0.7 percent CC. There was statistically no 
significant association with smoking and any of IL-6 gene 
polymorphisms when smoking as a risk was compared 
against BPH non smoking study subjects.  
The effect of alcohol and IL-6 polymorphism towards 
risk of prostate cancer among cases and controls is given 
in Table 5. The percentages of the three genotypes of IL-
6 among cases were 24.7 GG, 14 GC and 2.7 CC. The 
relative risk of alcohol and IL-6 174 G>C polymorphism of 
cases   was   computed   against   non   drunker   healthy  
  
 
 
 
 
Table 5 Risk of prostate cancer in drinkers due to IL-6-174 G-C polymorphisms among cases and controls. 
 
 
Genotype  
       Alcoholic   
OR (95% CI) 
       Non drinkers     
 OR (95% CI) cases Controls  cases Controls   
GG 37 (24.7%) 30 (20%) 1.21 (0.90-
1.65) 
45(ref.)   
(30%) 
54(ref.)   
(36%) 
1.0 Ref. 
GC 21 (14%) 27 (18%) 0.931.98) 
(0.44- 
33 (22%) 31 (20.7%) 0.99 (0.47-2.10) 
CC 4 (2.7%) 4 (2.7%) 1.10 (0.53-
2.27) 
10 (6.7%) 4 (2.7%) 1.23 (0.59-2.57) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (Centre for disease control and prevention). 
 
Table 6 Risk of prostate cancer in drinkers due to IL-6-174 G-C polymorphisms among cases and BPH. 
 
 
Genotype  
       Alcoholic   
OR (95% CI) 
       Non drinkers     
 OR (95% CI) cases BPH cases BPH 
GG 37 (24.7%) 31 (20.7%) 1.14 (0.84-
1.54)  
45 ((ref.)  
30%) 
49 (ref.)  
(32.7%) 
1.0 Ref.  
GC 21 (14%) 27 (18.0%) 0.85 (0.40-
1.81) 
33 (22%) 33 (22%) 0.84 (0.40-1.79) 
CC 4 (2.7%) 4 (2.7%) 1.04 (0.51-
2.16) 
10 (6.7%) 6 (4%) 0.93 (0.42-2.06) 
 
OR= odds ratio, CI= Confidence interval, OR was computed by Epi-Info version 3.5.1. (Centre for disease control and prevention). 
 
controls. There was statistically no significant association 
to any of the genotypes of IL-6 alcoholism and risk of 
prostate cancer.  
The OR and 95 % CI of IL-6 174 G-C polymorphism 
and effect of alcohol among cases and BPH subjects 
were computed in Table 6. There were 20.7% GG, 18% 
GC and 2.7% CC genotype carriers among alcoholic 
BPH study subjects. The effect of alcohol in risk of 
prostate cancer among cases was computed against non 
alcoholic BPH subjects. There was statistically no 
significant association between alcohol and 
polymorphism of IL-6 genotypes when compared to BPH 
non alcoholic study subjects.  
 
 
DISCUSSION  
 
Interleukin-6 (IL-6) is a pleiotropic growth factor involved 
in many physiological and pathological processes 
including carcinogenesis (Ishihara and Hirano, 2002). 
Chronic inflammation plays a role in transformation from 
normal cell to malignant state. Interleukin-6 (IL-6) 
regulates inflammation and various physiological 
processes. IL-6 promoter polymorphism (−174G>C) is 
associated with transcription differences in vitro and in 
vivo. High expression of IL-6 may result in oxidative DNA 
damage and enhance risk of carcinogenesis (Upadhyay 
et al., 2008).  High serum levels of IL-6 have been 
associated with advanced stage disease and worse 
prognosis for several cancer types including ovarian, 
breast and colorectal (Berek et al., 1991; Zhang and 
Adachi, 1999; Belluco et al., 2003). In contrast, however, 
high levels of IL-6 protein and mRNA expression within 
the breast carcinoma tissue have been linked to better 
prognosis and to a less malignant phenotype (Basolo et 
al., 1996). A common G>C polymorphism located within 
the IL-6 promoter at position -174 has been reported to 
influence IL-6 expression, with the G allele being 
associated with higher expression levels (Fishman et al., 
1998; Terry et al., 2000; Vickers et al., 2002). This 
polymorphism has been implicated in a number of 
chronic disease conditions including arthritis, coronary 
heart disease and diabetes (Fishman et al., 1998; 
Fernandez-Real et al., 2000). In human cancer, the _174 
G/C IL-6 polymorphism does not appear to be a risk 
factor for the development of multiple myeloma or 
melanoma (Zheng et al., 2000). Data, however, suggest 
that the C allele is associated with an increased risk of 
colorectal cancer (Landi et al., 2003). Furthermore, in 
ovarian cancer, the C allele is associated with an earlier 
stage of disease and with significantly better survival 
(Hefler et al., 2003).  
In the present study this important polymorphism was 
evaluated for risk of prostate cancer in 150 prostate 
patients from north Indian population. There was 
statistically significance association between this 
polymorphism and risk of prostate cancer.  Similar results 
has been reported by  Dominique et al. (2006) and Xu et 
al. (2005) who found a direct relationship between 
polymorphisms of IL-6–174G>C and risk of prostate 
cancer  in European and American people. However, Bao 
et al. (2008) found null results in Han people living in 
Hubei regions, China.  We believe that the discrepancy 
might be ascribed, to the fact that the polymorphism of –
174G/C has ethnic difference.   The results of this study 
are not consistent with the findings of other related 
studies in China (Zhai et al., 2001 and Liu et al., 2005), 
which   further   suggests   that   the   polymorphism   of – 
  
 
 
 
 
174G>C in Chinese is different from that of European and 
American people but is close to that of oriental people 
such as Japanese and Korean (Lim et al., 2002).  
Despite prostate cancer  the association of IL-6 −174 
G>C polymorphism with risk of several malignancies and 
inflammatory diseases such as  juvenile chronic arthritis 
(Fish man et al., 1998), Kaposis sarcomas, (Foster et al., 
2000), colorectal cancer (Bullcuo et al., 2003), ovarian 
cancer (Hefler et al., 2003), Hodgkin lymphoma (Cozen 
et al., 2004), non small cell lung cancer (Campa et al., 
2004), prostate cancer (Tan et al., 2005), and peripheral 
arterial disease has been reported for different ethnic 
background.  
Elevated levels of IL-6 in serum and malignant tissues 
have also been shown to be associated with poor 
prognosis of esophageal cancer (OKa et al., 1996; Wang 
et al., 1999). The reason behind the association of IL-6 
genotype with susceptibility of esophageal cancer may be 
due to blocked cytotoxic function of tumor-infiltrating 
lymphocytes by high local IL-6 concentrations at tumor 
sites (Tanner et al., 1999). Thus, it is possible that 
increased IL-6 production in −174C non-carriers may lead 
to escape of esophageal tumor cells from immune 
surveillance and promote oncogenesis (Oka et al., 1996). 
Earlier studies also showed association of elevated 
serum IL-6 level with esophageal tumor stage, lymph 
node metastasis and with poor prognosis (Wang et al., 
1999). The persistence of the pro-inflammatory cytokine 
IL-6 response maintains chronic recruitment of 
lymphocytes and mast cells which stimulates schemas 
cell carcinoma invasion and metastasis. Once carcinoma 
in situ penetrates the basement membrane to involve the 
lamina propria, it is invasive carcinoma and capable of 
widespread dissemination. Therefore, understanding the 
interplay of genes and the pathways they utilize can lead 
to the detection of novel molecular targets in the 
diagnosis, prognosis, and treatment of cancers. 
Environmental factors like smoking and alcohol are well 
established mediators of high risk in cancer such as 
esophageal (van Leeuwen et al., 2007). Accordingly, in 
this study statistically significant additional risk of prostate 
cancer was observed in cases due to smoking. However, 
different results for oesophageal cancer was described 
by Upadhyay et al. (2008) who reported in their study that 
interaction of IL-6 −174G>C polymorphism with 
environmental factors (like tobacco usage, alcohol or 
household combustible fuels) did not modulate the risk of 
esophageal cancer.  This discrepancy might be explained 
by difference in study design, difference in ethical 
background and small statistical power.  
Similar studies with large sample size are warranted to 
determine the role of environmental factors like smoking 
and drinking alcohol and association of IL-6-174 G>C 
polymorphism and  risk of prostate cancer both in the 
same and different ethnic backgrounds since the  role  of  
 
 
 
 
 
alcohol and smoking in prostate cancer risk in the 
literature is not consistence.  
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